Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMECB4H)

• Drug Name: Levopropoxyphene Napsylate Anhydrous Drug Info
• Synonyms: Novrad

Indication

Disease Entry	ICD 11	Status	REF
Cough	MD12	Approved	[1]

• Cross-matching ID:
  PubChem CID: 6604497
  CAS Number: CAS 5714-90-9
  TTD Drug ID: DMECB4H

Molecule-Related Drug Atlas

Drug(s) Targeting Opioid receptor mu (MOP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Buprenorphine	DMPRI8G	Opioid dependence	6C43.2Z	Approved	[3]
Morphine	DMRMS0L	Advanced cancer	2A00-2F9Z	Approved	[4]
Hydromorphone	DMHP21E	Back pain	ME84.Z	Approved	[5]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[6]
Fentanyl	DM8WAHT	Analgesia	MB40.8	Approved	[7]
Alfentanil	DMVO0UB	Anaesthesia	9A78.6	Approved	[8]
Naloxegol	DML0B41	Opioid-induced constipation	DB32.1	Approved	[9]
Eluxadoline	DMYZ0P1	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[10]
Nalfurafine hcl	DMA9DHW	Uremic pruritus	EC90.10	Approved	[11]
Oxycodone	DMXLKHV	Osteoarthritis	FA00-FA05	Approved	[12]

Drug(s) Targeting Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TC-5214	DM8AM60	Palmar hyperhidrosis	EE00.00	Phase 2	[13]
18-MC	DMGE3DY	Substance use disorder	6C4Z	Phase 1	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4)	TT35UGH	ACHA3_HUMAN-ACHB4_HUMAN	Modulator	[2]
Opioid receptor mu (MOP)	TTKWM86	OPRM_HUMAN	Modulator	[2]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [3] Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
• [4] Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
• [5] Clinical pipeline report, company report or official report of signaturerx.
• [6] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [7] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [8] Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
• [9] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [10] Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
• [11] Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)